4 results
Primary ObjectivesTo assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects withAlzheimer*s disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025Secondary ObjectivesTo assess the duration…
Primary• To evaluate the progression free survival (PFS), based on independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or unresectable stage IIIB/IV adenocarcinoma non-…
Assess whether: trimetazidine treatment 1) improves LV diastology; 2) improves LV myocardial energy content in HFpEF.
Main objective: to measure the effect of trimetazidine on myocardial external efficiency in asymptomatic MYH7, MYBPC3 or TNNT2 mutation carriers Secondary objectives: to study the effect of trimetazidine on diastolic function, left ventricle and…